$TVGN
Tevogen Bio Holdings Inc. Stock $tvgn

$tvgn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224016796 Filed on April 29, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$2.274M	$2.274M
YoY Change		968.66%	138.59%
% of Gross Profit
Research & Development	$4.124M
YoY Change	73.4%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$8.599M	-$4.560M	$2.274M
YoY Change	1533.0%	-2242.86%	138.58%
Operating Profit	-$8.599M
YoY Change	293.64%
Interest Expense		$611.0K	$256.0K
YoY Change		-87.87%	-95.22%
% of Operating Profit
Other Income/Expense, Net		$48.87M	$2.207M
YoY Change		-2144.21%	-58.84%
Pretax Income		$56.78M	-$67.30K
YoY Change		2071.67%	-101.53%
Income Tax
% Of Pretax Income
Net Earnings	-$9.663M	$56.78M	-$67.33K
YoY Change	4854.19%	2071.67%	-101.53%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04
Diluted Earnings Per Share	-$0.04	$0.37	$0.00
COMMON SHARES
Basic Shares Outstanding	164.6M shares
Diluted Shares Outstanding	154.2M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$9.000K	$9.000K
YoY Change		-93.03%	-93.03%
Cash & Equivalents	$1.135M	$8.835K
Short-Term Investments
Other Short-Term Assets		$3.000K	$3.000K
YoY Change		-97.93%	-97.93%
Inventory
Prepaid Expenses
Receivables		$345.0K	$345.0K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$2.447M	$355.8K	$356.0K
YoY Change	249.87%	29.7%	29.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$377.5K	$458.7K
YoY Change	-66.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$16.68M	$16.68M
YoY Change
Other Assets	$133.3K	$271.1K
YoY Change	-99.48%	-99.92%
Total Long-Term Assets	$863.5K	$16.68M	$16.68M
YoY Change	-96.64%	-95.33%	-95.33%
TOTAL ASSETS
Total Short-Term Assets	$2.447M	$355.8K	$356.0K
Total Long-Term Assets	$863.5K	$16.68M	$16.68M
Total Assets	$3.310M	$17.04M	$17.04M
YoY Change	-87.45%	-95.23%	-95.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.666M	$3.418M	$1.142M
YoY Change	859.28%	1524.32%	442.65%
Accrued Expenses	$1.776M	$1.096M
YoY Change	101.37%
Deferred Revenue
YoY Change
Short-Term Debt		$1.632M	$1.632M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.61M	$3.004M	$3.004M
YoY Change	597.87%	757.21%	757.18%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$14.73M	$14.73M
YoY Change		0.15%	0.15%
Total Long-Term Liabilities		$14.73M	$14.73M
YoY Change		0.15%	0.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.61M	$3.004M	$3.004M
Total Long-Term Liabilities		$14.73M	$14.73M
Total Liabilities	$10.94M	$17.73M	$17.73M
YoY Change	-32.65%	17.77%	17.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$98.06M	-$17.38M
YoY Change	530.52%	17.54%
Common Stock	$16.88K	$12.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.634M	-$17.38M	-$696.0K
YoY Change
Total Liabilities & Shareholders Equity	$3.310M	$17.04M	$17.04M
YoY Change	-87.45%	-95.23%	-95.23%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$9.663M	$56.78M	-$67.33K
YoY Change	4854.19%	2071.67%	-101.53%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		$4.818M	-$1.376M
YoY Change		-34839.01%	538.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$342.9M	$342.9M
YoY Change
Cash From Investing Activities		$343.0M	$342.9M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$343.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-345.1M	-$341.7M
YoY Change
NET CHANGE
Cash From Operating Activities		4.818M	-$1.376M
Cash From Investing Activities		343.0M	$342.9M
Cash From Financing Activities		-345.1M	-$341.7M
Net Change In Cash		2.757M	-$120.4K
YoY Change		-19979.6%	-44.13%
FREE CASH FLOW
Cash From Operating Activities		$4.818M	-$1.376M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	TVGN	Class B Ordinary Shares ClassBOrdinaryShares		usd
CY2022	TVGN	Impairment Of Amount Due From Related Party ImpairmentOfAmountDueFromRelatedParty		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	TVGN	Noncash Interest Expenses NoncashInterestExpenses		usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent		usd
CY2022	TVGN	Extension Amount Deposited Into Trust Account ExtensionAmountDepositedIntoTrustAccount		usd
CY2022	TVGN	Proceeds From Cash Withdrawn From Trust Account In Connection With Redemption ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022	TVGN	Sale Of Class B Shares To Investor SaleOfClassBSharesToInvestor		usd
CY2022	TVGN	Sale Of Warrants SaleOfWarrants		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	25451000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	164614418	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, CA
CY2023Q4	us-gaap	Cash Cash	8835	usd
CY2022Q4	us-gaap	Cash Cash	129186	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2501	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	145170	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	355836	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	274356	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	16681497	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	356864000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1142405	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	210454	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1631725	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	230000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	140000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3004130	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	350454	usd
CY2023Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	29000	usd
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	7250	usd
CY2023Q4	TVGN	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	14700000	usd
CY2022Q4	TVGN	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	14700000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	17733130	usd
CY2022Q4	us-gaap	Liabilities Liabilities	15057704	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	16681497	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	356864000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	TVGN	Class A Ordinary Shares ClassAOrdinaryShares	1343	usd
CY2022Q4	TVGN	Class A Ordinary Shares ClassAOrdinaryShares	145	usd
CY2022Q4	TVGN	Class B Ordinary Shares ClassBOrdinaryShares	1198	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17378637	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14784691	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-17377294	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14783348	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17037333	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	357138356	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2273970	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	953083	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	2273970	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	953083	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2734426	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4948194	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21750	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-413250	usd
CY2023	TVGN	Impairment Of Amount Due From Related Party ImpairmentOfAmountDueFromRelatedParty	250000	usd
CY2023	us-gaap	Interest Expense InterestExpense	256031	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2206645	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5361444	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4408361	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14783348	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	275306	usd
CY2023	TVGN	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-2801927	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-67325	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-17377294	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-14227709	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-14227709	usd
CY2022	TVGN	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-4964000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4408361	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14783348	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14783348	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-67325	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4408361	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2734426	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4948194	usd
CY2023	TVGN	Noncash Interest Expenses NoncashInterestExpenses	256031	usd
CY2023	TVGN	Impairment Of Amount Due From Related Party ImpairmentOfAmountDueFromRelatedParty	250000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21750	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-413250	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-142669	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-446609	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	267000	usd
CY2023	us-gaap	Increase Decrease In Due To Affiliates Current IncreaseDecreaseInDueToAffiliatesCurrent	90000	usd
CY2022	us-gaap	Increase Decrease In Due To Affiliates Current IncreaseDecreaseInDueToAffiliatesCurrent	120000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	931950	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	171079	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1376351	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-215395	usd
CY2023	TVGN	Extension Amount Deposited Into Trust Account ExtensionAmountDepositedIntoTrustAccount	67500	usd
CY2023	TVGN	Proceeds From Cash Withdrawn From Trust Account In Connection With Redemption ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption	342984430	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	342916930	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1323500	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	342984430	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-341660930	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-120351	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-215395	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129186	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	344581	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8835	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129186	usd
CY2023	TVGN	Change In Value Of Class Ordinary Shares Subject To Redemption Amount ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount	2801927	usd
CY2022	TVGN	Change In Value Of Class Ordinary Shares Subject To Redemption Amount ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount	4964000	usd
CY2023	TVGN	Sale Of Class B Shares To Investor SaleOfClassBSharesToInvestor	3955111	usd
CY2023	TVGN	Sale Of Warrants SaleOfWarrants	20000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zDJFUh9gK4b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_006"></span>Note 1 — <span id="xdx_82B_zbRh0MYh8YDi">Description of Organization, Business Operations and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Semper Paratus Acquisition Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on April 21, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with <span id="xdx_907_ecustom--ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_dc_uInteger_c20230101__20231231_zMWGIEMfvKxj" title="Condition for future business combination number of businesses minimum">one</span> or more businesses (the “Business Combination”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had not commenced any operations. All activity through December 31, 2023, relates to the Company’s formation and Initial Public Offering (“IPO”), which is described below, and the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income earned on investments from the proceeds derived from the IPO. The registration statement for the Company’s IPO was declared effective on November 3, 2021. On November 8, 2021, the Company consummated the IPO of <span id="xdx_908_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_pid_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLHmTymUPMXd" title="Units Issued During Period, Shares, New Issues">30,000,000</span> units (“Units”) with respect to the ordinary shares included in the Units being offered (the “Public Shares”) at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNGHyHlxNe89" title="Purchase price, per unit">10.00</span> per Unit generating gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjIs6le75hF" title="Proceeds from Issuance Initial Public Offering">300,000,000</span>, which is discussed in Note 3. The company has selected December 31 as its fiscal year end.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously with the closing of the IPO, the Company consummated the sale of <span id="xdx_90A_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq6Kw3dFp78a" title="Units Issued During Period, Shares, New Issues">1,360,000</span> private placement units (“Private Placement Units”) at a price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbYk6jXFSDU4" title="Purchase price, per unit">10.00</span> per Private Placement Unit in a private placement to the Company’s sponsor, Semper Paratus Sponsor LLC (the “Original Sponsor”) and underwriter Cantor Fitzgerald & Co. (“Cantor”) generating gross proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zaiAenvmmHFe" title="Proceeds from Issuance Initial Public Offering">13,600,000</span> which is described in Note 4.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously with the closing of the IPO, the Company consummated the closing of the sale of <span id="xdx_906_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBqlRFJutaP6" title="Units issued during period, shares new">4,500,000</span> additional Units upon receiving notice of the underwriter’s election to fully exercise its overallotment option (“Overallotment Units”), generating additional gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zyVOD8AzgT2c" title="Proceeds from issuance initial public offering">45,000,000</span> and incurring additional offering costs of $<span id="xdx_90A_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zcZlqCYYSBH" title="Deferred offering costs noncurrent">2,700,000</span> in underwriting fees all of which are deferred until completion of the Company’s Business Combination. Simultaneously with the exercise of the overallotment, the Company consummated the Private Placement of an additional <span id="xdx_900_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zDYXZViuAVrl" title="Common equity securities">90,000</span> Private Placement Units to the Original Sponsor, generating gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zSlgdCB6G0e7" title="Proceeds from issuance initial public offering">900,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering costs for the IPO amounted to $<span id="xdx_90D_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zM0kMRZ02hRe">21,266,594</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, consisting of $<span id="xdx_90E_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6hPQ2q0R0Ue">6,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of paid underwriting fees, $<span id="xdx_90E_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zCkiu10bqmKi">14,700,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $<span id="xdx_90A_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zoUEDVkE0YGh" title="Other offering costs">566,594 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of other costs. On June 28, 2023, the Company and Cantor entered into a fee reduction agreement (the “Fee Reduction Agreement”), pursuant to which Cantor agreed to forfeit $<span id="xdx_90F_ecustom--DeferredOfferingCostsNoncurrentForfeited_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zn4kU3FxyPk9" title="Deferred underwriting fees">9,700,000</span> of the deferred underwriting fees payable, resulting in a remainder of $<span id="xdx_909_ecustom--DeferredOfferingCostsNoncurrent_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zEO3SgCutDUk" title="Deferred offering costs non current">5,000,000</span> of deferred underwriting fees payable (the “Reduced Deferred Fee”) by the Company to Cantor upon the closing of the Transaction (as defined below) with Tevogen Bio Inc (“Tevogen Bio”), such fee payable to Cantor in the form of <span id="xdx_903_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20230628__20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zzt6gdXHo7od" title="Common equity securities">500,000</span> shares of the common equity securities of the entity surviving the Transaction. The Fee Reduction Agreement only applies to the consummation of the Transaction with Tevogen Bio and no other potential Business Combinations that may be contemplated or consummated by the Company. In the event that the Company were not to complete the Transaction with Tevogen Bio, the Original Deferred fee would become due and payable by the Company to Cantor as originally set forth in the Underwriting Agreement, upon the consummation of a Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the closing of the IPO, $<span id="xdx_908_ecustom--PaymentsForInvestmentOfCashInTrustAccount_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3KspCMAjPDj" title="Payments for investment of cash in trust account">351,900,000</span> ($<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMPFV6fwpes3" title="Purchase price, per unit">10.20</span> per Unit) from the net proceeds of the sale of the Units in the IPO and the Private Placement Units was placed in a trust account (“Trust Account”) and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. As of December 31, 2023, there is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least <span id="xdx_909_ecustom--ConditionForFutureBusinessCombinationUseOfProceedsPercentage_iI_dp_uPure_c20231231_z45et9GfPFY7" title="Condition for future business combination use of proceeds percentage">80</span>% of the assets held in the Trust Account excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires <span id="xdx_90C_ecustom--ConditionForFutureBusinessCombinationThresholdPercentageOwnership_iI_pid_dp_c20231231_z76yREbwvLV6" title="Condition for future business combination threshold ownership (as a percent)">50</span>% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN BIO HOLDINGS INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER 31, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will provide the holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZaHgeiI0YXh" title="Purchase price, per unit">10.20</span> per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to the Company’s warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s amended and restated memorandum and articles of association (the “Memorandum and Articles of Association”). In accordance with Accounting Standards Codification (“ASC”) 480-10-S99, redemption provisions not solely within the control of a company require Class A ordinary shares subject to redemption to be classified outside of permanent equity. Given that the Public Shares were issued with other freestanding instruments (i.e., public warrants), the initial carrying value of ordinary shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The ordinary shares are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. While redemptions cannot cause the Company’s net tangible assets to fall below $<span id="xdx_901_ecustom--ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_iI_c20231231_zqwayskvZtv6" title="Net tangible assets">5,000,001</span>, the Public Shares are redeemable and are classified as such on the balance sheet until such date that a redemption event takes place.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemptions of the Company’s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to an agreement relating to the Company’s Business Combination. If the Company seeks shareholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a shareholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 30, 2023, shareholders (the “Initial Shareholders”) holding all of the issued and outstanding Class B ordinary shares (the “Founder Shares”) of the Company elected to convert their Class B ordinary shares into Class A ordinary shares of the Company on a <span id="xdx_907_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_zeBYVwN7gdDk" title="Conversion ratio">one</span>-for-one basis (the “Conversion”). As a result, <span id="xdx_90D_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z2ZYNNSqJV0e" title="Shares cancelled">11,983,333</span> of the Company’s Class B ordinary shares were cancelled and <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqQyyjgoU3Cc" title="Shares issued upon conversion">11,983,333</span> Class A ordinary shares were issued to such converting Class B shareholders. The Initial Shareholders agreed that all of the terms and conditions applicable to the Founder Shares set forth in the Letter Agreement, dated November 3, 2021, by and among the Company, its officers, its directors and the Initial Shareholders (the “Letter Agreement”), shall continue to apply to the Class A ordinary shares that the Founder Shares converted into, including the voting agreement, transfer restrictions and waiver of any right, title, interest or claim of any kind to the Trust Account (as defined in the Letter Agreement) or any monies or other assets held therein. Following the Conversion, on January 30, 2023, the Company had <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zP1gjbscAhqh" title="Common stock, shares outstanding">47,933,333</span> Class A ordinary shares issued and outstanding and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgySFaZSCsnl" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zwX2xLaD0Bne" title="Common stock, shares outstanding">no</span></span> Class B ordinary shares issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN BIO HOLDINGS INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER 31, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 3, 2023, the Company’s shareholders approved an amendment (the “First Extension Charter Amendment”) to the Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial Business Combination from February 8, 2023 to December 15, 2023. Under Cayman Islands law, the First Extension Charter Amendment took effect upon approval by the shareholders. In connection with the meeting, shareholders holding approximately <span id="xdx_904_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_z33fQd6UXHD2" title="Minimum period to file charter amendment">32,116,947</span> Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $<span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember_zqFSwarHdFjd" title="Cash withdrawn from Trust Account in connection with redemption">333</span> million (approximately $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrnaTqrsici1" title="Price per share">10.38</span> per Public Share) was removed from the Trust Account to pay such holders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 14, 2023, the Company’s shareholders approved an amendment (the “Second Extension Charter Amendment”) to the Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial Business Combination to September 15, 2024. Under Cayman Islands law, the Second Extension Charter Amendment took effect upon approval by the shareholders. In connection with the meeting, shareholders holding approximately <span id="xdx_90A_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zXYa3o808VCk" title="Minimum period to file charter amendment">880,873</span> Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $<span id="xdx_90F_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn4n6_c20231214__20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember_zt1tLSiARXGi" title="Cash withdrawn from trust account in connection with redemption">9.71</span> million (approximately $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrf2ccm725nh" title="Price per share">11.03</span> per Public Share) was removed from the Trust Account to pay such holders. Approximately $<span id="xdx_907_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pn5n6_c20231231_zQKEGPZSGhh3" title="ash and marketable securities held in Trust Account">16.7</span> million remained in the Trust Account as of December 31, 2023 and the Company had <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zLJ4vIkIdKbh" title="Common stock shares outstanding">1,502,180</span> public shares outstanding as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 4, 2023, the Company entered into a purchase agreement (the “Purchase Agreement”) with SSVK Associates, LLC (the “Sponsor”) and the Original Sponsor, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zH5jDdhu5VY7" title="Stock issued during period, Shares new issues">7,988,889</span> Class A ordinary shares and (y) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zlLyy02ze1qi" title="Stock issued during period, Shares new issues">1,000,000</span> Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Letter Agreement, dated November 3, 2021, by and among the Company, its officers, directors and the Original Sponsor, and the Underwriting Agreement, dated November 3, 2021, by and between the Company and Cantor, as representative of the several underwriters (the “Underwriting Agreement”)), for an aggregate purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zVaC2L3t6W2e" title="Purchase price, per unit">1.00</span> (the “Purchase Price”) payable at the time of the initial Business Combination (see Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, the Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of <span id="xdx_907_ecustom--RedemptionLimitPercentageWithoutPriorConsent_dp_uPure_c20230101__20231231_ztHl250zlGz5" title="Redemption limit percentage without prior consent">15</span>% or more of the ordinary shares sold in the IPO, without the prior consent of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Initial Shareholders have agreed not to propose an amendment to the Memorandum and Articles of Association that would affect the substance or timing of the Company’s obligation to redeem <span id="xdx_905_ecustom--PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_dp_uPure_c20230101__20231231_z7I1R0qtqSv7" title="Obligation to redeem public shares if entity does not complete a business combination (as a percent)">100</span>% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is unable to complete a Business Combination by September 15, 2024 (“Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to us to pay the Company’s franchise and income taxes (less up to $<span id="xdx_909_ecustom--MaximumAllowedDissolutionExpenses_c20230101__20231231_zVAJkI5epihf" title="Maximum allowed dissolution expenses">100,000</span> of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. On December 18, 2023, the Company deposited $<span id="xdx_902_eus-gaap--AssetsHeldInTrust_iI_c20231218_zVShfNGa696i" title="Extension amount deposited into Trust Account">67,500</span> into the Trust Account in order to extend the date by which the Company has to complete the initial business combination by three months from December 14, 2023, to March 15, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN BIO HOLDINGS INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER 31, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to its deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNODw1vph2m4" title="Shares issued, price per share">10.20</span> per share held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i> Business Combination</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On June 28, 2023, the Company entered into an Agreement and Plan of Merger by and among the Company, Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), the Sponsor, in its capacity as purchaser representative, Tevogen Bio, and Ryan Saadi, in his capacity as seller representative (as may be amended and/or restated from time to time, the “Merger Agreement”), pursuant to which, among other things, the parties will affect the merger of Merger Sub with and into Tevogen Bio, with Tevogen Bio continuing as the surviving entity (the “Merger”), as a result of which all of the issued and outstanding capital stock of Tevogen Bio shall be exchanged for shares of Class A common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230628__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zDptEao3aUA7" title="Ordinary shares, par value (in dollar per share)">0.0001</span> per share (the “Class A Common Stock”), of the Company (the “Share Exchange”) subject to the conditions set forth in the Merger Agreement, with Tevogen Bio surviving the Share Exchange as a wholly owned subsidiary of the Company (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the “Transaction”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On September 14, 2023, the Company filed a registration statement on Form S-4 with the SEC relating to the Transaction with Tevogen, and on February 14, 2024, the Company consummated the Transaction. See Note 10 for more information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity and Going Concern</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had $<span id="xdx_906_eus-gaap--Cash_iI_c20231231_zODOpYi3K2e6" title="Cash">8,835</span> in its operating bank accounts, $<span id="xdx_906_eus-gaap--AssetsHeldInTrustNoncurrent_iI_c20231231_z9lqJZcCJUD4" title="Assets held in trust noncurrent">16,681,497</span> in cash held in the Trust Account to be used for a Business Combination or to repurchase or redeem its ordinary shares in connection therewith and working capital deficit of $<span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_c20231231_zSxmpiZut0Td" title="Working capital deficit">2,648,294</span>. As of December 31, 2023, approximately $<span id="xdx_903_eus-gaap--InvestmentIncomeInterest_c20230101__20231231_zlzvEPktqM16" title="Investment income interest">2,734,000</span> of the amount on deposit in the Trust Account represented interest income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company management believes that cash on hand following consummation of the Transaction as well as $<span id="xdx_904_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7QPqAiWlDL">2,000,000 </span>to the Company from a Series A Preferred Stock financing in February 2024 and $<span id="xdx_905_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zt1yebqOBlpe">1,200,000</span> in connection with the Series A-1 Preferred Stock financing thereafter (see Note 10) is not sufficient to sustain planned operations for 12 months from the issuance date of these financial statements. As a result, the Company has concluded that substantial doubt exists about its ability to continue as a going concern for one year from the date that these financial statements are issued. The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Management is currently evaluating different strategies to obtain the additional funding for future operations for subsequent years. These strategies may include but are not limited to private placements of equity and/or debt, licensing and/or marketing arrangements, and public offerings of equity and/or debt securities. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN BIO HOLDINGS INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER 31, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023	TVGN	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1	integer
CY2023Q4	TVGN	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	0.80	pure
CY2023Q4	TVGN	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	0.50	pure
CY2023Q4	TVGN	Condition For Future Business Combination Threshold Net Tangible Assets ConditionForFutureBusinessCombinationThresholdNetTangibleAssets	5000001	usd
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1	pure
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	16700000	usd
CY2023	TVGN	Redemption Limit Percentage Without Prior Consent RedemptionLimitPercentageWithoutPriorConsent	0.15	pure
CY2023	TVGN	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2023	TVGN	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000	usd
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	67500	usd
CY2023Q4	us-gaap	Cash Cash	8835	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	16681497	usd
CY2023Q4	TVGN	Working Capital Deficit WorkingCapitalDeficit	2648294	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2734000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zzoVedJkZirl">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zcm94hOGvmZ9">Concentration of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount">250,000</span>. At December 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	TVGN	Impairment Of Amount Due From Related Party ImpairmentOfAmountDueFromRelatedParty	250000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	351900000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4964000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	356864000	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	2801927	usd
CY2023	TVGN	Temporary Equity Redemption Amount TemporaryEquityRedemptionAmount	-342984430	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	16681497	usd
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.0680	pure
CY2023Q2	TVGN	Stock Price Of Measurement StockPriceOfMeasurement	10.77	shares
CY2023Q2	TVGN	Probability Of Transaction Percentage ProbabilityOfTransactionPercentage	0.0440	pure
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2023Q4	TVGN	Working Capital WorkingCapital	17000	usd
CY2023	TVGN	Impairment Of Amount Due From Related Party ImpairmentOfAmountDueFromRelatedParty	250000	usd
CY2023	TVGN	Impairment Of Amount Due From Related Party ImpairmentOfAmountDueFromRelatedParty	250000	usd
CY2023Q2	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	46139	usd
CY2023Q2	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	229167	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1631725	usd
CY2023Q4	TVGN	Convertible Notes Payable Discounts ConvertibleNotesPayableDiscounts	275306	usd
CY2023	TVGN	Noncash Interest Expenses NoncashInterestExpenses	256031	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	19274	usd
CY2023	TVGN	Underwriting Cash Discount Per Unit UnderwritingCashDiscountPerUnit	0.20
CY2023	TVGN	Underwriting Cash Discount Per Unit UnderwritingCashDiscountPerUnit	0.20
CY2023	TVGN	Aggregate Underwriter Cash Discount AggregateUnderwriterCashDiscount	900000	usd
CY2023Q4	TVGN	Deferred Fee Per Unit DeferredFeePerUnit	0.40
CY2023	TVGN	Aggregate Deferred Underwriting Fee Payable AggregateDeferredUnderwritingFeePayable	14700000	usd
CY2023	TVGN	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	13800000	usd
CY2023	TVGN	Underwriter Cash Discount UnderwriterCashDiscount	900000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares

Files In Submission

Name	View Source	Status
0001493152-24-016796-index-headers.html	Edgar Link	pending
0001493152-24-016796-index.html	Edgar Link	pending
0001493152-24-016796.txt	Edgar Link	pending
0001493152-24-016796-xbrl.zip	Edgar Link	pending
ex10-13.htm	Edgar Link	pending
ex10-14.htm	Edgar Link	pending
ex10-15.htm	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-3.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvgn-20231231.xsd	Edgar Link	pending
tvgn-20231231_lab.xml	Edgar Link	unprocessable
tvgn-20231231_pre.xml	Edgar Link	unprocessable
tvgn-20231231_cal.xml	Edgar Link	unprocessable
tvgn-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVGN
Tevogen Bio Holdings Inc. Stock $tvgn

2024 Q2 Form 10-K Financial Statement

#000149315224016796 Filed on April 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVGN Tevogen Bio Holdings Inc. Stock $tvgn

2024 Q2 Form 10-K Financial Statement

#000149315224016796 Filed on April 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVGN
Tevogen Bio Holdings Inc. Stock $tvgn